Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

5370 - Evaluation of different diagnostic methods for identification of FGFR alteration in advanced urothelial carcinomas: Proficiency Results based on multiple RNA extraction kits and mutation detection methods


30 Sep 2019


Poster Display session 3


Tumour Site

Urothelial Cancer


Veronika Weyerer


Annals of Oncology (2019) 30 (suppl_5): v356-v402. 10.1093/annonc/mdz249


V.E.J. Weyerer1, R. Stoehr1, H. Juette2, R. Wirtz3, M. Eckstein1, F. Roghmann4, J. Breyer5, S. Porubsky6, D. Sikic7, C. Bolenz8, M.C. Kriegmair9, A. Hartmann10, P. Erben11

Author affiliations

  • 1 Institute Of Pathology, Universitätsklinik Erlangen, 91054 - Erlangen/DE
  • 2 Department Of Pathology, Ruhr University Bochum, Bochum/DE
  • 3 On Behalf Of The Bridge-consortium E.v., STRATIFYER Molecular Pathology GmbH, Cologne, 50935 - Cologne/DE
  • 4 Urologic Department Of The Ruhr - University Bochum, Marienhospital Herne, 44625 - Herne/DE
  • 5 Department Of Urology, University of Regensburg, Regensburg/DE
  • 6 Institute Of Pathology, Medical Faculty Mannheim, University of Heidelberg, Mannheim/DE
  • 7 Department Of Urology And Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen/DE
  • 8 Department Of Urology, University of Ulm, Ulm/DE
  • 9 Urology, University Hospital Mannheim, Ruprecht-Karls-University Heidelberg, Mannheim, 68159 - Mannheim/DE
  • 10 Institute Of Pathology, Universitätsklinik Erlangen, 91052 - Erlangen/DE
  • 11 Department Of Urology Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim/DE


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5370


Pan FGFR inhibitors such as Erdafitinib are approved in patients with advanced urothelial carcinoma (aUC) harboring FGFR alterations. Based on the necessity of sensitive and reproducible identification of these alterations in diagnostic routines this study aimed to compare different RNA isolation techniques and the QIAGEN therascreen® FGFR RGQ RT-PCR Kit with the SNaPshot mutational analysis.


Nucleic acids were extracted from 47 UC patients using the QIAGEN RNeasy® DSP FFPE Kit, STRATIFYER Xtract or Maxwell RNA (Promega) isolation kit. Mutations of the FGFR3 gene were detected using the SNaPshot method as well as via the QIAGEN therascreen® FGFR RGQ RT-PCR Kit. Intrinsic molecular subtypes were assessed using immunohistochemistry (IHC) of GATA3, FOXA1, CK20, CK5 and CD44 as well as RT-qPCR for gene expression of CK20 and CK5.


All three different RNA isolation kits showed comparable amount of extracted RNA (Median 290, 177 and 226 ng/ul). Six hotspot FGFR3 mutations were identified with 100% concordance. The main difference were the necessary working hours: per 10 samples, 4 vs. 4.5 vs 8 hours were needed for Stratifyer, Maxwell or QIAGEN RNA isolation. In addition, of 47 analyzed samples 100% concordance between QIAGEN therascreen® FGFR RGQ RT-PCR Kit and SNapShot analysis were achieved with 18 mutations identified (14 S249C, 2 R248C and 2 Y375). Immunohistochemical basal marker profile (CD44 and CK5) as well as high CK5 expression was observed in 28 (6/28 FGFR3-altered). Luminal marker profile (IHC markers: GATA3, FOXA1 and CK20 as well as expression of CK20) was detected in 37 samples (5/37 with FGFR3 alteration, n.s.).


Different RNA extraction methods presented with comparable amount of nucleic acids with variant working hours. Moreover, a 100% concordance between the well established SNaPshot analysis compared to the QIAGEN therascreen® FGFR RGQ RT-PCR Kit for FGFR3 mutations was observed. So far, the frequency of FGFR3 mutations in aUC was not related to the type of UC as defined by marker profils.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

BRIDGE consortium.




R. Wirtz: Officer / Board of Directors: Stratifyer. M. Eckstein: Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Janssen. A. Hartmann: Advisory / Consultancy: Janssen. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.